Abstract. The aim of the present study was to select key genes that are associated with fibroblasts and keratinocytes during keloid scar progression and development. The gene expression profile of GSE44270, which includes 32 samples, was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) in case samples compared with control samples were screened using the Limma R package followed by hierarchical clustering analysis. Protein-protein interaction (PPI) networks of the total selected DEGs were constructed using Cytoscape. Moreover, the Gene Ontology biological processes and significant Kyoto Encyclopedia of Genes and Genomes pathways of the total selected DEGs were enriched using the Database for Annotation, Visualization and Integrated Discovery. Significant pathways that may be associated with keloid scar were analyzed using deviation analysis of dynamic capabilities. There were 658 DEGs in fibroblast keloid vs. normal, 112 DEGs in fibroblast non-lesion vs. normal, 439 DEGs in fibroblast keloid vs. non-lesion, 523 DEGs in keratocyte keloid vs. normal, 186 DEGs in keratocyte non-lesion vs. normal, and 963 DEGs in keratocyte keloid vs. non-lesion groups. HOXA9, BMP4, CDKN1A and SMAD2 in fibroblasts, and HOXA7, MCM8, PSMA4 and PSMB2 in keratinocytes were key genes in the PPI networks. Moreover, the amino sugar and nucleotide sugar metabolism pathway, cell cycle, and extracellular matrix (ECM)-receptor interaction pathway were significant pathways. This study suggests that several key genes (BMP4, HOXA9, SMAD2, CDKN1A, HOXA7, PSMA4 and PSMB2) that participate in some significant pathways (cell cycle and ECM-receptor interaction pathways) may be potential therapeutic targets for keloid scars.
Introduction
Keloid scar of skin is a soft tissue benign skin tumor that originates from the proliferation of connective tissue following skin injury (1) . Data show that the morbidity of keloid scars has been high in recent years, and female cases are more common than male cases (2) . There are a variety of clinical treatment methods for keloids, including glucocorticoid injection under the skin, freezing, compression, ultrashort wave therapy, and simple surgery (3, 4) . However, clinical data reveal that the therapeutic effects are poor due to easy recurrence and high morbidity (5) . Therefore, it is necessary to explore some biomarkers for keloid scar therapy in clinical practice.
The pathogenesis of keloid scar formation is complicated, particularly the key roles of fibroblasts and keratinocytes in this type of disease (6, 7) . Werner et al demonstrated that keratinocytes interact with fibroblasts and then function in wound healing (8) . Keloid-derived keratinocytes were shown to perform a promoting role on fibroblast growth and proliferation in an in vitro study (7) . Furthermore, there is increasing evidence that many key molecules play crucial roles during keloid scar development through fibroblasts and keratinocytes from a molecular perspective. For instance, downregulation of the inhibitors SMAD6 and SMAD7 was found in keloid scar tissue (9) , and overexpression of bone morphogenetic protein (BMP)2 contributed to fibroblast cell proliferation and collagen synthesis during cholesteatoma progression (10) . Although many researchers have focused on the pathogenesis of fibroblasts and keratinocytes in keloid scar development and progression, the molecular mechanism remains incompletely elucidated.
Gene expression analysis provides the basis for predicting target genes that are associated with many diseases. Hahn et al investigated abnormally expressed genes in keloid keratinocytes and fibroblasts using the GSE44270 microarray (11) . In the present study, the expression of functional genes of keloid keratinocytes and fibroblasts was analyzed using the same gene expression profile. The downloaded files were preprocessed using the R package in the Robust Multi-array Analysis (RMA) method (12) . The probe IDs were transformed into gene bank IDs using Database for Annotation, Visualization and Integrated Discovery (DAVID) software (13) .
DEG screening. The DEGs in case samples compared with the control samples were screened using the R package in Limma (14) . An adjusted P-value based on false discovery rate (FDR) of <0.01 (15) and log 2 |fold change (FC)| >1 were chosen as the thresholds.
Hierarchical clustering analysis of DEGs. In order to identify the selected DEGs from different tissue samples, hierarchical clustering was used to analyze the total selected DEGs from the fibroblast or keratinocyte samples using the Python programming language (16) . Also, Pearson correlation was used to establish the similarity matrix of DEGs (17) , and the type of linkage used was the average linkage (18) .
Protein-protein interaction (PPI) network construction.
In order to investigate the potential genes that interacted with the selected DEGs, the total screened DEGs were used to construct a PPI network based on the BioGRID database (19) and the Human Protein Reference Database (HPRD) database (20) . Cytoscape (21) was used to conduct a topological analysis of the constructed network to study the node degrees of the DEGs.
Functional enrichment analysis of the DEGs. The biological processes and significant pathways for the total selected DEGs in the six groups were enriched using the DAVID online software with (Gene Ontology) GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms. Terms with DEG number >10 and P<0.05 were selected as they were considered to be significant terms.
Deviation analysis of dynamic capabilities. The enriched biological processes and pathways of DEGs in the three groups (non-lesion vs. normal, keloid vs. normal and keloid vs. non-lesion) suggested some significant pathways that were involved in the process of skin and scar pathogenesis from normal to non-lesion, and then to skin and scar disease. The dynamic capability of each significant pathway term was calculated with the following formula (22): P represents function, A(P) represents the deviation score, N represents the number of DEGs, X i represents the average expression value for one DEG i in disease development, Yi represents the average gene expression value for one gene i in normal tissues, and ω represents the node degree for DEG i in the PPI network. Euclidean distances of the total DEGs between case samples and normal samples were calculated to predict the deviation degree of DEGs in case samples (non-lesion or keratocyte keloid) compared with the normal samples.
Results

DEG screening and hierarchical clustering analysis.
The total DEGs in the six groups were selected using the Limma package with an adjusted P-value <0.01 and log 2 |FC| >1 compared with the control samples (Table I ). There were 658 DEGs in the fibroblast keloid vs. normal group, 112 DEGs in the fibroblast non-lesion vs. normal group, 439 DEGs in the fibroblast keloid vs. non-lesion group, 523 DEGs in the keratocyte keloid vs. normal group, 186 DEGs in the keratocyte non-lesion vs. normal group, and 963 DEGs in the keratocyte keloid vs. non-lesion group. A Venn plot of the total screened DEGs is shown in Fig. 1A ; there were 2 common DEGs in keratinocytes and 1 common DEG in fibroblasts during the progression of skin and scar pathogenesis. In addition, the hierarchical clustering of the DEGs in each group is shown in Fig. 1B. PPI network construction. The screened DEGs in the different groups were used to construct the PPI network. The results showed that there were a total of 456 nodes (83 upregulated, 92 downregulated and 281 other DEGs obtained between lesion and non-lesion tissues) in the PPI network of DEGs in keratinocytes (Fig. 2) , and there were a total of 374 nodes (74 upregulated, 181 downregulated, and 119 other DEGs obtained between lesion and non-lesion tissues) in the PPI network of DEGs in fibroblasts (Fig. 3) . The results showed that DEGs such as homeobox A9 (HOXA9), BMP4, and phosphoinositide-3-kinase, regulatory subunit 1 α (PIK3R1) were upregulated while cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), and SMAD family member 2 (SMAD2) were downregulated in fibroblasts. Also, DEGs including HOXA7, minichromosome maintenance complex component 8 (MCM8), and GRB2-associated binding protein 1 (GAB1) were upregulated while proteasome (prosome, macropain) subunit, α type, 4 (PSMA4), PSMB2, and cyclin-dependent kinase 1 (CDK1) were downregulated in keratinocytes. In addition, structure specific recognition protein 1 (SSRP1) was a common gene in both keratinocytes and fibroblasts; however, it was only upregulated in fibroblast samples.
Functional enrichment analysis of the DEGs in each group.
The significant biological processes and pathways of screened DEGs in fibroblast and keratinocyte groups were analyzed (Table II) . The results revealed that DEGs in fibroblast samples were enriched in significant GO terms such as negative regulation of cellular biosynthetic process, organ morphogenesis, and chordate embryonic development (Table IIA) , and the total DEGs were involved in significant pathways such as the amino sugar and nucleotide sugar metabolism pathway and the extracellular matrix (ECM)-receptor interaction pathway (Table IIB) . In addition, DEGs in keratinocyte samples were enriched in significant GO terms such as M phase, DNA metabolic process, and M phase of mitotic cell cycle (Table IIA) , and the DEGs participated in the significant pathways of spliceosome, cell cycle, and DNA replication (Table IIB) .
Deviation analysis of dynamic capabilities.
A total of 16 pathways of DEGs from the fibroblast and keratinocyte groups were analyzed for deviation of dynamic capabilities (Fig. 4) . Scores of pathways such as chondroitin sulfate biosynthesis (0.09) and oocyte meiosis (0.19) in the non-lesion group, and base excision repair (0.17), homologous recombination (0.17), and pyrimidine metabolism (0.17) in the lesion group indicated that DEGs involved in these pathways were similar to those in normal tissues (Table III) . Furthermore, amino sugar and nucleotide sugar metabolism (0.09) and aminoacyl tRNA biosynthesis (0.07) in the non-lesion group, and base excision repair (0.17), homologous recombination (0.17), and pyrimidine metabolism (0.17) in the lesion group suggested that DEGs involved in these pathways were similar to those of DEGs in normal tissues (Table III) .
Discussion
Keloid scar of skin is a type of benign soft tissue skin tumor that originates from the proliferation of connective tissue subsequent to skin injury, and has high morbidity (1,2). The identification of some clinical biomarkers for keloid scars would be of great significance. In the present study, the gene expression profile of GSE44270 was analyzed to screen A B several key genes for skin and keloid scars and investigate the mechanisms involving fibroblasts and keratinocytes in keloid scar progression. The results demonstrated that many key genes that are involved in several significant pathways are crucial for keloid scars. The present data indicated that BMP4 and HOXA9 are upregulated, and SMAD2 and CDKN1A are downregulated during the development and progression in fibroblasts. BMP4 is a protein of the bone morphogenetic family that belongs to the transforming growth factor superfamily, and is reported to play crucial roles in fibroblast proliferation (23) , and an imbalance between proliferation and apoptotic cells in fibroblasts has been shown to be associated with keloids (24) . Russell et al demonstrated that decreased expression of HOXA9 was correlated with wound healing in keloid-derived fibroblasts (25) . Thus, overexpression of HOXA9 and BMP4 may contribute to the development of keloid scarring of the skin. SMAD2 is a SMAD family protein that functions as a signal transducer and transcriptional modulator in multiple signaling pathways (26) . Gao et al demonstrated that silencing SMAD2 with siRNA modulated the synthesis of collagen in keloid-derived fibroblasts (27) , and Cohen et al suggested that collagen synthesis may suppress keloid scarring (28) . CDKN1A is a cyclin-CDK2 complex protein that functions as a regulator of cell cycle Table III . Pathway alteration scores of DEGs in different groups. progression at G1 (29) , and the accumulation of the cell cycle regulator CDKN1A has been linked to human fibroblast proliferation (30) . Therefore, the downregulation of SMAD2 and CDKN1A may promote the progression of keloids. The present study suggests that cell cycle pathway is the significant pathway in keloid-derived fibroblasts tissue. Based on our data, it may be speculated that BMP4, HOXA9, SMAD2 and CDKN1A are suppressors for fibroblasts in keloids and function through the cell cycle pathway.
Score of the enriched pathways of DEGs
The results of the present study also indicated that HOXA7 is upregulated, and PSMA4, PSMB2 and CDK1 are downregulated during the development and progression of keloids in keratinocyte tissues. HOXA7 is a transcription factor that is encoded by HOX family genes, and a previous study has revealed abnormal HOX gene expression in normal keratinocytes (31). Hyland et al showed that HOXA7 is able to silence differentiation-specific genes in keratinocytes (32) . Hence, HOXA7 may be a suppressor for progression in keloid-derived keratinocytes. PSMA4 and PSMB2 are two proteins of the PSM protein family that have key functions in keratinocytes (33) . The roles of PSMA4 and PSMB2 in keloid-derived keratinocytes have not been fully defined. However, Amos et al suggested that PSMA4 may be associated with susceptibility to keloids (34) , and Lim reported that PSMB2 was correlated with keloid therapy exosome (35) . The ECM-receptor interaction pathway was found to be a common pathway in the two types of keloid-derived cells. Gene bioinformatics analysis has shown that the ECM-receptor interaction pathway, which is associated with several key genes, is significant in keloids (36) . Based on the present results, it is speculated that HOXA7 may be a suppressor while PSMA4 and PSMB2 may contributors in keloid-derived keratinocytes through the ECM-receptor interaction pathway.
In conclusion, the present study identified key genes involved in keloid-derived fibroblasts (BMP4, HOXA9, SMAD2, and CDKN1A) and keratinocytes (HOXA7, PSMA4, and PSMB2) during keloid development and progression through several key pathways such as cell cycle and ECM-receptor interaction pathways. The results may provide a theoretical basis for the mechanistic investigation of keloid scar pathogenesis. However, further studies are required to verify the predicted results.
